Your session is about to expire
← Back to Search
Decision Support Tool for Atrial Fibrillation
N/A
Waitlist Available
Led By Larry Jackson
Research Sponsored by Duke University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Clinical diagnosis of NVAF
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up end of study, 12 months
Awards & highlights
Study Summary
This trial is testing whether a patient decision support tool will help patients make better decisions about oral anticoagulation for stroke reduction in non-valvular atrial fibrillation, especially Black patients.
Who is the study for?
This trial is for Black and White adults over 18 with non-valvular atrial fibrillation (NVAF) who have a CHA2DS2-VASc score of at least 2, indicating a higher risk of stroke. They must be new patients at primary care or cardiology clinics considering starting oral anticoagulation but cannot participate if they can't speak English or provide informed consent.Check my eligibility
What is being tested?
The study tests whether a patient decision support tool can improve the quality of decisions made by patients regarding the use of oral anticoagulants to prevent strokes in NVAF. It aims to see if this tool helps, especially among Black patients, and will assess its feasibility and acceptability.See study design
What are the potential side effects?
Since this trial involves using a decision support tool rather than medication, there are no direct side effects from drugs being tested. However, participants may experience stress or anxiety when making treatment decisions.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have been diagnosed with non-valvular atrial fibrillation.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ end of study, 12 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~end of study, 12 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Percent of patients who stated that the intervention was acceptable as measured by patient and provider interviews.
Proportion of patients willing to consent as measured by enrollment log
Proportion of patients willing to participate as measured by enrollment log
+2 moreSecondary outcome measures
Decision Quality measured by use of the decision conflict scale
Decision to initiate systemic oral anticoagulation measured and documented by physician of record during clinic visit.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Patient Decision Support ToolExperimental Treatment1 Intervention
Patient decision support tool to be used in conjunction with physician counseling to discuss the risk and benefits of systemic oral anticoagulation.
Group II: Usual Healthcare CounselingActive Control1 Intervention
Traditional physician counseling regarding the risk and benefits of systemic oral anticoagulation
Find a Location
Who is running the clinical trial?
National Institutes of Health (NIH)NIH
2,696 Previous Clinical Trials
6,952,548 Total Patients Enrolled
9 Trials studying Atrial Fibrillation
1,212 Patients Enrolled for Atrial Fibrillation
Duke UniversityLead Sponsor
2,358 Previous Clinical Trials
3,420,029 Total Patients Enrolled
13 Trials studying Atrial Fibrillation
13,281 Patients Enrolled for Atrial Fibrillation
Larry JacksonPrincipal InvestigatorDuke University
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am starting oral anticoagulation treatment at a primary care or cardiology clinic.I have been diagnosed with non-valvular atrial fibrillation.I am unable to understand or sign the consent form.I am an adult aged 18 or older.You have a score of 2 or more on the CHA2DS2-VASc scale.
Research Study Groups:
This trial has the following groups:- Group 1: Patient Decision Support Tool
- Group 2: Usual Healthcare Counseling
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are additional volunteers being accepted for this medical research experiment?
"Unfortunately, the information on clinicaltrials.gov does not suggest that this particular trial is currently seeking patients for enrollment; it was posted in July 2023 and last updated in August 2022. However, there are 477 other trials throughout which participants may be recruited at present."
Answered by AI
Recent research and studies
Share this study with friends
Copy Link
Messenger